Iradimed Q4 Revenue to Reach $25 Million to $26.5 Million

The medical equipment maker plans to scale production and lift margins to 77% as it manages new hardware output.

Updated on Oct. 30, 2026 in Economic Indicators

Isometric editorial illustration of a sterile medical device housing and metallic component on a workspace, representing precision manufacturing and output strategy. — Iradimed expects fourth-quarter 2026 revenue to hit $25 million to $26.5 million as the medical device maker focuses on controlled production of its hardware. AI Illustration. Upload story photo >

Live Poll

Does consistent revenue growth in medical device companies make you trust their long-term stability?

Iradimed projects fourth-quarter 2026 revenue between $25 million and $26.5 million as production of its 3870 systems continues. The company anticipates a return to historical profit margins while ramping up shipments of its MR IV pump technology.

Why it matters

The company is balancing growth in its medical equipment segment with controlled production rates to ensure product quality. Monitoring these output shifts provides insight into the company's ability to maintain high margins while meeting demand for specialized hardware.

Iradimed reports a 76% gross margin for the third quarter of 2026, with forecasts aiming to move back into a historical range of 77% to 78% by the end of the year. The company expects revenue from its 3870 MR IV pump to see sequential growth exceeding 50% in the fourth quarter.

The players

Iradimed

A developer of specialized medical equipment, including MR IV pumps, that provides hardware to healthcare facilities.

The details

Iradimed is strategically pacing the manufacturing of its 3870 medical systems to prioritize quality control. By limiting production volume, the firm aims to optimize operations and support higher profit margins as it scales the distribution of its MR IV pump technology. This controlled production cycle is intended to align output with operational standards before shifting toward higher revenue targets.

Iradimed produced over 400 3870 systems during the third quarter of 2026.
The projected revenue window covers the fourth quarter of 2026.

Money Landscape

Iradimed is navigating an operational phase that benchmarks current output against the firm's historical gross margin range of 77% to 78%. This effort follows a third-quarter performance where the company produced over 400 systems while maintaining a 76% margin.

Healthcare providers utilizing these specialized systems may see availability trends shift as the company prioritizes product quality over high-volume output. Interested parties should consult with a professional advisor regarding the company's long-term operational health.

The takeaway

The firm is prioritizing high quality-control standards, which dictates the pace of its medical equipment delivery throughout the end of 2026. Investors and budget planners should watch for future margin disclosures to see if the company successfully returns to its 77% to 78% target range.